{"id":"tafluprost-timolol-fixed-combination","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Eye irritation/discomfort"},{"rate":null,"effect":"Increased iris pigmentation"},{"rate":null,"effect":"Eyelash growth"},{"rate":null,"effect":"Bradycardia (timolol component)"}]},"_chembl":{"chemblId":"CHEMBL1963683","moleculeType":"Small molecule","molecularWeight":"452.54"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tafluprost binds to prostaglandin F (FP) receptors on the ciliary muscle and trabecular meshwork, enhancing drainage of aqueous humor through the uveoscleral pathway. Timolol blocks beta-2 adrenergic receptors in the ciliary body, reducing aqueous humor secretion. The combination provides complementary mechanisms to lower intraocular pressure more effectively than either agent alone.","oneSentence":"Tafluprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor, while timolol is a non-selective beta-blocker that decreases aqueous humor production, together reducing intraocular pressure.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:10:56.535Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT03822559","phase":"PHASE3","title":"A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2019-01-20","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":219},{"nctId":"NCT04828057","phase":"","title":"Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting","status":"COMPLETED","sponsor":"Santen Pharmaceutical (Taiwan) Co., LTD","startDate":"2021-09-01","conditions":"Ocular Surface Disease, Primary Open Angle Glaucoma","enrollment":50},{"nctId":"NCT04673604","phase":"NA","title":"From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple Glaucoma Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2018-05-06","conditions":"Glaucoma, Ocular Surface Disease","enrollment":42},{"nctId":"NCT05299593","phase":"PHASE4","title":"24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or Ocular Hypertensive Patients Already Treated With Latanoprost Preserved With BAK. A Prospective, Open Study of 3 Months Duration.","status":"UNKNOWN","sponsor":"Fondazione G.B. Bietti, IRCCS","startDate":"2020-06-04","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":43},{"nctId":"NCT03612817","phase":"PHASE4","title":"Preservative-free Tafluprost/Timolol Fixed Combination: Morning vs Evening Dosing","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2017-01","conditions":"Glaucoma, Open-Angle","enrollment":42},{"nctId":"NCT02802137","phase":"PHASE4","title":"24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2015-03","conditions":"Glaucoma, Ocular Surface Disease","enrollment":43},{"nctId":"NCT01263444","phase":"PHASE4","title":"Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-03","conditions":"Glaucoma, Ocular Hypertension","enrollment":47},{"nctId":"NCT01292460","phase":"PHASE3","title":"Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies","status":"COMPLETED","sponsor":"Santen Oy","startDate":"2011-02","conditions":"Ocular Hypertension, Open-angle Glaucoma","enrollment":600},{"nctId":"NCT01434888","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops","status":"COMPLETED","sponsor":"Santen Oy","startDate":"2011-09","conditions":"Healthy Volunteers","enrollment":15},{"nctId":"NCT01306461","phase":"PHASE3","title":"Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations","status":"COMPLETED","sponsor":"Santen Oy","startDate":"2011-03","conditions":"Ocular Hypertension, Open-angle Glaucoma","enrollment":401}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Taptiqom"],"phase":"marketed","status":"active","brandName":"Tafluprost/timolol fixed combination","genericName":"Tafluprost/timolol fixed combination","companyName":"Aristotle University Of Thessaloniki","companyId":"aristotle-university-of-thessaloniki","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tafluprost/timolol fixed combination is used to treat conditions such as open-angle glaucoma and ocular hypertension. It works as a prostanoid FP receptor agonist, which is a type of prostaglandin F2-alpha receptor agonist.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}